oral lichen planus
Conditions
Interventions
hydroxychloroquine group:hydroxychloroquine for the treatment of oral lichen planus companying diabetes mellitus
compound glycyrrhisim group:compound glycyrrhisim for the treatment of oral lichen planus companying diabetes mellitus
Sponsors
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Patient with the ability to give informed, dated and signed consent; 2) Aged 18 to 75 years old; 3) Patients who are diagnosed as Oral Lichen Planus by history,clinical manifestations and pathological examination; 4) DM criteria: those who have been diagnosed.If there is no previous history, the fasting blood glucose (FPG) should be =7 mmol/L or OGTT2 hours blood glucose =11.1 mmol/L; glycosylated hemoglobin is =6.5%. Repeat inspection twice is up to standard; 5) The treatment plan is constant and the blood glucose is stable.
Exclusion criteria
Exclusion criteria: 1) Patients with other established oral mucosal disease; 2) There is an unstable, serious, or acute progression of liver or kidney disease, such as ALT or AST > 2 times the upper limit of normal value, BUN > 1.5 times the upper limit of the normal value, creatinine > 1.5 times the upper limit of the normal value; 3) Antibiotics are used within 1 months, and those who have used the immune agent within 3 months; 4) Severe and uncontrolled systemic diseases, such as blood system disease, or had a history of congestive heart failure, ventricular dysfunction, or any situation that influence the effect of treatment and evaluation of results, or to ensure the completion of the study or not; 5) Pregnant and lactating women; 6) Can not follow the doctor's medication or research process is not complete,or affect the judge; 7) Patients with fundus disease; 8) Expected to survive for less than 3 months; 9) During the 12 months prior to the visit,patients are alcoholism or drug dependence .There is a significant risk for any subjects who are unable to complete the study or to participate in the study; 10) Clinically significant abnormal results of a physical examination or an electrocardiogram which may affect the investigator's judgment about whether the patient is safe or able to complete the clinical study; 11) Patients who are allergic to hydroxychloroquine or compound glycyrrhizin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| glycosylated hemoglobin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting plasma glucose;Sign score;Symptom score; | — |
Countries
China
Contacts
Public ContactXuemin Shen
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed